TENX
What one share of Tenax Therapeutics holds
Pharmaceutical Preparations
Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. We employ a clinician-driven drug development approach, led by key opinion leaders and heart failure experts and informed by their clinical insights to precisely target disease pathophysiology.
Tenax Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.47 |
| Cash and investments | $3.69 |
| Book value | $3.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $5.24 | −$281.49 | $0.25 | −$119.57 | — | — |
| 2013 | $13.54 | −$133.67 | $0.20 | −$56.15 | — | — |
| 2014 | $0.34 | −$54.14 | $0.02 | −$19.81 | — | — |
| 2015 | $0.04 | −$10.03 | $0.00 | −$6.95 | — | — |
| 2016 | $0.00 | −$31.24 | $0.00 | −$11.29 | — | — |
| 2017 | — | −$6.27 | $0.00 | −$8.61 | — | — |
| 2018 | — | −$9.04 | $0.00 | −$3.52 | — | — |
| 2019 | — | −$1.35 | $0.00 | −$1.22 | — | — |
| 2020 | — | −$0.95 | $0.00 | −$0.89 | — | — |
| 2021 | — | −$1.58 | $0.00 | −$0.53 | — | — |
| 2023 | — | −$31.04 | — | −$23.76 | — | $27.15 |
| 2024 | $0.00 | −$1.15 | — | −$0.97 | — | — |
| 2025 | $0.00 | −$1.34 | — | −$0.91 | — | $10.42 |